Development of Novel Radiogallium-Labeled Bone Imaging Agents Using Oligo-Aspartic Acid Peptides as Carriers

Kazuma Ogawa¹, Atsushi Ishizaki¹, Kenichiro Takai¹, Yoji Kitamura², Tatsuto Kiwada¹, Kazuhiro Shiba², Akira Odani¹

¹ Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ² Advanced Science Research Center, Kanazawa University, Kanazawa, Japan

Abstract

⁶⁷Ga (T₁/₂ = 68 min, a generator-produced nuclide) has great potential as a radionuclide for clinical positron emission tomography (PET). Because poly-glutamic and poly-aspartic acids have high affinity for hydroxyapatite, to develop new bone targeting⁶⁷Ga-labeled bone imaging agents for PET, we used 1,4,7,10-tetraazaacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a chelating site and conjugated aspartic acid peptides of varying lengths. Subsequently, we compared Ga complexes, Ga-DOTA-(Asp)ₙ (n = 2, 5, 8, 11, or 14) with easy-to-handle ⁶⁷Ga, with the previously described ⁶⁷Ga-DOTA complex conjugated bisphosphonate, ⁶⁷Ga-DOTA-Bn-SCN-HBP. After synthesizing DOTA-(Asp)ₙ by a Fmoc-based solid-phase method, complexes were formed with ⁶⁷Ga, resulting in ⁶⁷Ga-DOTA-(Asp)ₙ with a radiochemical purity of over 95% after HPLC purification. In hydroxyapatite binding assays, the binding rate of ⁶⁷Ga-DOTA-(Asp)ₙ increased with the increase in the length of the conjugated aspartate peptide. Moreover, in biodistribution experiments, ⁶⁷Ga-DOTA-(Asp)₉ ⁶⁷Ga-DOTA-(Asp)₁₁, and ⁶⁷Ga-DOTA-(Asp)₁₄ showed high accumulation in bone (10.5 ± 1.5, 15.1 ± 2.6, and 12.8 ± 1.7% ID/g, respectively) but were barely observed in other tissues at 60 min after injection. Although bone accumulation of ⁶⁷Ga-DOTA-(Asp)₉ was lower than that of ⁶⁷Ga-DOTA-Bn-SCN-HBP, blood clearance of ⁶⁷Ga-DOTA-(Asp)₉ was more rapid. Accordingly, the bone/blood ratios of ⁶⁷Ga-DOTA-(Asp)₁₁ and ⁶⁷Ga-DOTA-(Asp)₁₄ were comparable with those of ⁶⁷Ga-DOTA-Bn-SCN-HBP. In conclusion, these data provide useful insights into the drug design of ⁶⁸Ga-PET tracers for the diagnosis of bone disorders, such as bone metastases.

Introduction

Bone contains abundant proliferation factors, and is therefore a convenient environment for tumors to metastasize and grow. Indeed, malignant tumors frequently metastasize to the bone [1]. With the development of therapeutic methods and drugs, early diagnoses of bone metastases must be more important. Significant advances in imaging technologies such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI) have been made during the last a few decades; however, because of its high sensitivity, nuclear medicine bone scanning is the optimal test for detecting bone metastases. Over the last thirty years, ⁹⁹mTc-labeled bone imaging agents for bone diagnoses of bone metastases must be more important. Significant advances in imaging technologies such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI) have been made during the last a few decades; however, because of its high sensitivity, nuclear medicine bone scanning is the optimal test for detecting bone metastases. Over the last thirty years, ⁹⁹mTc-mononuclear complex-conjugated ⁹⁹mTc-bisphosphonate complexes, the phosphonate groups coordinate with not only Ca²⁺ but also ⁹⁹mTc, which might decrease the inherent accumulation of bisphosphonate (MDP or HMPD) in bone. Incidentally, ⁹⁹mTc-bisphosphonate complexes cannot be isolated as well-defined single chemical species, but as mixtures of short- and long-chain oligomers, may reduce the efficacy of radiopharmaceuticals. Biological behaviors of these tracers are also affected by the degree of ionization and by variable oligomer constitutions of preparations [11]. To overcome the shortcomings of ⁹⁹mTc-bisphosphonate complexes, we and other groups have designed and developed ⁹⁹mTc-mononuclear complex-conjugated
biphosphonate compounds [12–15], in which phosphonate groups are not coordinated with 99mTc. As expected, some of these compounds showed superior biodistribution compared with previous compounds. Of note, this drug concept is applicable to both 99mTc-complex radiopharmaceuticals and other radiometals [16–26].

Sodium fluoride labeled with 18F (18F-NaF) for bone imaging was initially reported by Blau et al. in 1962 [27], and subsequently was approved by FDA in 1972. 18F-NaF accumulates in bone because fluoride anions are isomorphously exchanged with the hydroxyl group in hydroxyapatite (Ca10(PO4)6(OH)2) and fluorapatite (Ca10(PO4)6F2) is formed. After the development of 99mTc-labeled bone scintigraphy agents, such as 99mTc-MDP, 18F-NaF was replaced by them because the physical characteristics of 99mTc were more convenient for imaging with conventional gamma cameras in those days. However, in the last two decades, positron emission tomography (PET) and PET/CT have evolved significantly and become widespread. The changes caused the reemergence of 18F-NaF and bone imaging agents for PET are desired because current PET have higher spatial resolution and greater sensitivity than conventional gamma cameras. Actually, it was reported that 18F-NaF PET imaging was significantly more sensitive than 99mTc-MDP planar and 99mTc-MDP single photon emission computed tomography (SPECT) imaging [28]. However, most positron emitters, such as 18F, need high cost cyclotron facilities, and it limits the availability for PET.

Meanwhile, the radionuclide 68Ga has great potential for clinical PET and could become an attractive alternative to 18F because of its radiophysical properties, particularly as a generator-produced nuclide with a half-life (T1/2) of 68 min [29]. Namely, it does not require an on-site cyclotron and can be eluted on demand. Indeed, in principle, the long half-life of the parent nuclide 68Ge (T1/2 = 270.8 days) provides a generator with a long life span. Therefore, the appearance of 68Ga-labeled compounds for bone imaging has been desired and some compounds have been reported in recent years [30–34].

Several noncollagenous bone proteins have repeating sequences of acidic amino acids (Asp or Glu) in their structures, offering potential hydroxyapatite-binding sites. For example, osteopontin and bone sialoprotein, 2 major noncollagenous bone matrix proteins, have repeating Asp and Glu rich sequences, respectively [35–37]. Reportedly, poly-glutamic and poly-aspartic acids have high affinity for hydroxyapatite and could be used to deliver drugs to bone tissues [38–40].

In this study, to develop new PET tracers for imaging bone disorders such as bone metastases, because it is well known that 68Ga forms a stable complex with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), DOTA was chosen as chelating agent. Subsequently, a series of Ga-DOTA-conjugated acidic amino acid peptides (Ga-DOTA-(Asp)n; Figure 1A) of varying peptide lengths (n = 2, 5, 8, 11, or 14) and (B) Ga-DOTA-Bn-SCN-HBP. [33] were purified by reversed-phase (RP)-HPLC performed with a Cosmosil 5C18-AR 300 column (10 x 150 mm; Nacalai Tesque, Kyoto, Japan) at a flow rate of 4 mL/min with an isocratic mobile phase of water containing 0.1% TFA [in the case of DOTA-(Asp)3] or with a Cosmosil 5C18-AR 300 column (10 x 150 mm; Nacalai Tesque, Kyoto, Japan) at a flow rate of 4 mL/min with a 0–20% methanol

**Materials and Methods**

**Materials**

Electrospray ionization mass spectra (ESI-MS) were obtained with a LCQ (Thermo Fisher Scientific, Waltham, MA, USA). Matrix assisted laser desorption/ionization-time of flight mass spectra (MALDI-TOF-MS) were obtained with ABI 4800 plus (AB SCIEX, Foster, CA, USA). [55]GaGac was supplied by Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-tris) was purchased from Macrocyclics (Dallas, TX, USA). 9-Fluorenlymethoxycarbonyl (Fmoc)-Asp(OtBu)-Wang resin and Fmoc-Asp(OtBu) were purchased from Merck KGaA (Darmstadt, Germany). Alendronate was synthesized according to the previous reported method [18]. Other reagents were of reagent grade and used as received.

**Synthesis of DOTA-(Asp)n**

The protected peptidyl resin was manually constructed by an Fmoc-based solid-phase methodology using Fmoc-Asp(OtBu)-Wang resin and Fmoc-Asp(OtBu). The peptide chain was constructed in cycles of (I) 15 minutes of deprotection with 20% piperidine in dimethylformamide (DMF) and (II) 2 hours of coupling with 3 equivalents of Fmoc-Asp(OtBu), 1,3-diisopropylcarbodiimide (DICDI), and 1-hydroxybenzotriazole hydrate (HOBt) in DMF. The coupling reaction was then repeated after Kaiser test was positive for the resin [41]. After construction of the peptide chain on the resin, the Fmoc protecting group was removed using 20% piperidine in DMF, and a mixture containing 2 equivalents of DOTA-tris, DICDI, and HOBt in DMF was added and allowed to react for 2 hours, as described above. To cleave peptides from the resin and deprotect, 0.5 mL of thioanisole and 5 mL of trifluoroacetic acid (TFA) were added to the fully protected peptide resin at 0°C and stirred at room temperature for 2 hours. After resin removal by filtration, ether was added to the filtrate at 0°C to precipitate crude peptide. The crude products were purified by reversed-phase (RP-HPLC) performed with a Hypersil 5C18 column (10 x 150 mm; YMC, Kyoto, Japan) at a flow rate of 4 mL/min with an isocratic mobile phase of water containing 0.1% TFA [in the case of DOTA-(Asp)3] or with a Hypersil 5C18 column (10 x 150 mm; Nacalai Tesque, Kyoto, Japan) at a flow rate of 4 mL/min with a 0–20% methanol
gradient mobile phase of 0.1% TFA in water over 20 minutes [in the case of DOTA-(Asp)n (n = 2, 5, 8, 11, or 14)], respectively. Chromatograms were obtained by monitoring the UV adsorption at a wavelength of 220 nm. The fraction containing DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) was determined by mass spectrometry, and collected. The solvent was removed by lyophilization to provide DOTA-(Asp)n as white powder.

DOTA-(Asp)2 MS [ESI]: m/z 635 (M+H)\(^+\), Yield : 22.0%
DOTA-(Asp)5 MS [ESI]: m/z 980 (M+H)\(^+\), Yield : 18.6%
DOTA-(Asp)8 MS [ESI]: m/z 1325 (M+H)\(^+\), Yield : 36.0%
DOTA-(Asp)11 MS [ESI]: m/z 1670 (M+H)\(^+\), Yield : 20.2%
DOTA-(Asp)14 MS [MALDI]: m/z 2015 (M+H)\(^+\), Yield : 5.0%

Preparation of Ga-DOTA-(Asp)n (n = 2, 5, 8, 11, or 14)

DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) (1 μmol) was dissolved in 75 μL of water, and Ga(NO\(_3\))\(_3\) (0.77 mg, 3 μmol) was added to the DOTA-(Asp)n solution. The mixture was reacted at 40°C for 2 hours. Ga-DOTA-(Asp)n was purified by RP-HPLC performed with a Hydroxyapatite-binding Assays

Preparation of 67Ga-DOTA-(Asp)n (n = 2, 5, 8, 11, or 14)

Approximately 50 μg of DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) conjugates were dissolved in 75 μL of 0.2 M ammonium acetate buffer (pH 5.0), and 25 μL of \(^{67}\text{GaCl}_3\) solution (1.85 MBq) in 0.01 M HCl was added and allowed to react at 80°C for 8 minutes. \(^{67}\text{Ga-DOTA-(Asp)}_n\) was purified by RP-HPLC under the conditions described for Ga-DOTA-(Asp)n.

Hydroxyapatite-binding Assays

Hydroxyapatite-binding assays were performed according to previous described procedures with slight modifications [33]. In brief, hydroxyapatite beads (Bio-Gel; Bio-Rad, Hercules, CA, USA) were suspended in Tris/HCl-buffered saline (50 mM, pH 7.4) at 2.5 mg/mL, 10 mg/mL, and 25 mg/mL. For the solutions of \(^{67}\text{Ga-DOTA-(Asp)}_n\) (n = 2, 5, 8, 11, or 14), the ligand concentrations were adjusted to 19.5 μM by adding DOTA-(Asp)n. Two hundred microliters of each \(^{67}\text{Ga-DOTA-(Asp)}_n\) solution was added to 200 μL of the hydroxyapatite suspension, and the samples were gently shaken for 1 hour at room temperature. After centrifugation at 10,000 g for 5 minutes, the radioactivity of the supernatant was measured using an auto well gamma counter (ARC-7010B, Hitachi Aloka Medical, Ltd., Tokyo, Japan). Control experiments were performed using the same procedure without hydroxyapatite beads, which showed less than 0.1% adsorption of radioactivity to vials. The ratios of binding were determined as follows:

\[
\text{Hydroxyapatite binding(%) = } \left(\frac{1-\text{sample supernatant radioactivity}}{\text{control supernatant radioactivity}}\right) \times 100
\]

The effect of bisphosphonate on the binding of \(^{67}\text{Ga-DOTA-(Asp)}_{14}\) or \(^{67}\text{Ga-DOTA-Bn-SCN-HBP}\) to hydroxyapatite beads was also examined. In these experiments, 100 μL of \(^{67}\text{Ga-DOTA-(Asp)}_{14}\) or \(^{67}\text{Ga-DOTA-Bn-SCN-HBP}\) solutions containing varying concentrations of the bisphosphonate compound alendronate were incubated with 100 μL of suspensions containing 1 mg of hydroxyapatite beads. After centrifugation, the radioactivity of the supernatant was measured, and hydroxyapatite-binding ratios were calculated as described above.

Biodistribution Experiments

Experiments with animals were conducted in strict accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. The animal experimental protocols used were approved by the Committee on Animal Experimentation of Kanazawa University ( Permit Number: AP-132633). Biodistribution experiments were performed after an intravenous administration of each diluted tracer solution (37 kBq/100 μL) to 6-week-old male ddY mice (27–32 g, Japan SLC, Inc., Hamamatsu, Japan). To investigate the effect of an excess amount of bisphosphonate on biodistribution, alendronate (20 mg/kg) was intravenously administered to mice 1 minute before the intravenous injection of \(^{67}\text{Ga-DOTA-(Asp)}_{14}\) or \(^{67}\text{Ga-DOTA-Bn-SCN-HBP}\). Four to six mice each were sacrificed by decapitation at 10, 60, and 180 minutes post-injection. Tissues of interest were removed and weighed. Complete left femurs were isolated as representative bone samples, radioactivity was determined using an auto well gamma counter, and counts were corrected for background radiation and physical decay during counting.

Protein-binding Assay

Serum protein binding ratios of \(^{67}\text{Ga-DOTA-(Asp)}_n\) (n = 2, 5, 8, 11, or 14) and \(^{67}\text{Ga-DOTA-Bn-SCN-HBP}\) were evaluated by an ultrafiltration method. In these experiments, 6-week-old male ddY mice received intravenous boluses of radiotracer. After 3 minutes,
the mice were anesthetized with ether, and blood was collected by heart puncture. Serum samples were prepared and applied to an Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-30 membrane (Millipore). The units were centrifuged at 14,000 g for 20 minutes at room temperature. The radioactivity counts of the initials and filtrates were determined using an auto well gamma counter. The protein-binding ratios were then calculated as follows:

\[
\text{Protein-binding ratio (\%)} = \frac{\text{radioactivity of filtrate}}{\text{radioactivity of initial solution}} \times 100
\]

Statistical Analysis
Data are expressed as means ± standard deviations where appropriate. In biodistribution experiments using alendronate as a blocking agent, differences were identified using unpaired Students’ t test and were considered significant when \( p < 0.05 \).

Results
Preparation of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) (n = 2, 5, 8, 11, or 14)
\( ^{67}\text{Ga-DOTA-(Asp)}_n \) (n = 2, 5, 8, 11, or 14) was prepared by complexation of DOTA-(Asp)_n with \( ^{67}\text{Ga} \). Radiochemical yields of \( ^{67}\text{Ga-DOTA-(Asp)}_2 \), \( ^{67}\text{Ga-DOTA-(Asp)}_5 \), \( ^{67}\text{Ga-DOTA-(Asp)}_8 \), \( ^{67}\text{Ga-DOTA-(Asp)}_{11} \), and \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) were 25\%, 67\%, 74\%, 56\%, and 51\%, respectively. After RP-HPLC purification, \( ^{67}\text{Ga-DOTA-(Asp)}_n \) had a radiochemical purity of over 95\%. Figure 2 shows typical chromatograms of \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) and Ga-DOTA-(Asp)_14. RP-HPLC analyses of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) and Ga-DOTA-(Asp)_n showed similar retention times, indicating that the radiogallium-labeled product was identical to its authentic nonradioactive counterpart.

Hydroxyapatite-binding Assay
Figure 3 shows the percentage of each \( ^{67}\text{Ga-DOTA-(Asp)}_n \) (n = 2, 5, 8, 11, or 14) that was bound to hydroxyapatite beads. Binding of each \( ^{67}\text{Ga-DOTA-(Asp)}_n \) to hydroxyapatite beads increased with the amount of hydroxyapatite. In contrast, \( ^{67}\text{Ga-DOTA} \) and \( ^{67}\text{Ga-DOTA-(Asp)}_2 \) hardly bound to hydroxyapatite beads. Moreover, hydroxyapatite binding of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) increased with the increase in the length of the aspartic acid chain. On the other hand, the binding of \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) and \( ^{67}\text{Ga-DOTA-Bn-SCN-HBP} \) was inhibited by the addition of a bisphosphonate compound alendronate in a concentration-dependent manner (Figure 4). Although \( ^{67}\text{Ga-DOTA-Bn-SCN-HBP} \) had higher affinity for hydroxyapatite than \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) (Figure 3), \( ^{67}\text{Ga-DOTA-Bn-SCN-HBP} \) appeared more susceptible to alendronate inhibition than \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) (Figure 4).

Biodistribution Experiments
The biodistributions of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) compounds (n = 2, 5, 8, 11, or 14) in normal mice are listed in Tables 1–5. Among these, \( ^{67}\text{Ga-DOTA-(Asp)}_5 \), \( ^{67}\text{Ga-DOTA-(Asp)}_{11} \), and \( ^{67}\text{Ga-DOTA-(Asp)}_{14} \) showed higher accumulation, and led to sustained radioactivity in the femur. Though \( ^{67}\text{Ga-DOTA-(Asp)}_2 \) led to moderate accumulation of radioactivity in the femur at 10 min after injection, the radioactivity was not retained. Meanwhile, \( ^{67}\text{Ga-DOTA-(Asp)}_2 \) hardly accumulated in the femur, and almost all injected radioactivity was rapidly excreted via the kidneys. Almost all radioactivity except radioactivity in bone after injection of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) compounds (n = 5, 8, 11, or 14) was also quickly excreted via the kidneys. Consequently, radioactivity was scarcely observed in any tissues except the bone and kidney at 60 minutes after injection of \( ^{67}\text{Ga-DOTA-(Asp)}_n \) compounds (n = 5, 8, 11, or 14).
Table 1. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_5$ in mice.

| Tissue                  | Time after administration | 10 min | 60 min | 180 min |
|-------------------------|---------------------------|--------|--------|---------|
| Blood                   |                           | 2.69 (0.42) | 0.24 (0.08) | 0.07 (0.06) |
| Liver                   |                           | 0.67 (0.11) | 0.31 (0.28) | 0.11 (0.02) |
| Kidney                  |                           | 11.77 (1.92) | 8.87 (4.09) | 1.31 (0.50) |
| Small-intestine         |                           | 0.57 (0.08) | 0.22 (0.12) | 0.08 (0.03) |
| Large-intestine         |                           | 0.46 (0.07) | 0.07 (0.01) | 0.40 (0.30) |
| Spleen                  |                           | 0.61 (0.01) | 0.14 (0.04) | 0.12 (0.02) |
| Pancreas                |                           | 0.76 (0.14) | 0.16 (0.05) | 0.08 (0.03) |
| Lung                    |                           | 2.10 (0.22) | 0.24 (0.06) | 0.08 (0.02) |
| Heart                   |                           | 0.98 (0.15) | 0.13 (0.05) | 0.06 (0.04) |
| Stomach                 |                           | 0.28 (0.05) | 0.07 (0.04) | 0.05 (0.04) |
| Bone (Femur)            |                           | 1.48 (0.31) | 0.80 (0.40) | 0.38 (0.15) |
| Muscle                  |                           | 0.75 (0.28) | 0.13 (0.05) | 0.07 (0.02) |
| Brain                   |                           | 0.08 (0.02) | 0.02 (0.01) | 0.01 (0.01) |
| F/B ratio$^a$           |                           | 0.55 (0.07) | 3.28 (1.23) | 8.04 (4.50) |

*Expressed as % injected dose. Each value represents the mean (SD) for four animals.

Table 2. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_8$ in mice.

| Tissue                  | Time after administration | 10 min | 60 min | 180 min |
|-------------------------|---------------------------|--------|--------|---------|
| Blood                   |                           | 2.18 (0.13) | 0.16 (0.04) | 0.02 (0.01) |
| Liver                   |                           | 0.44 (0.07) | 0.07 (0.01) | 0.04 (0.01) |
| Kidney                  |                           | 8.42 (1.82) | 3.61 (1.12) | 0.91 (0.27) |
| Small-intestine         |                           | 0.42 (0.06) | 0.11 (0.04) | 0.03 (0.01) |
| Large-intestine         |                           | 0.37 (0.04) | 0.19 (0.15) | 0.07 (0.01) |
| Spleen                  |                           | 0.50 (0.04) | 0.07 (0.02) | 0.03 (0.00) |
| Pancreas                |                           | 0.65 (0.07) | 0.13 (0.07) | 0.02 (0.00) |
| Lung                    |                           | 1.50 (0.13) | 0.15 (0.04) | 0.02 (0.01) |
| Heart                   |                           | 0.79 (0.08) | 0.07 (0.02) | 0.03 (0.01) |
| Stomach                 |                           | 0.24 (0.03) | 0.05 (0.02) | 0.03 (0.01) |
| Bone (Femur)            |                           | 6.36 (0.86) | 3.63 (0.29) | 1.76 (0.04) |
| Muscle                  |                           | 0.63 (0.21) | 0.09 (0.05) | 0.03 (0.01) |
| Brain                   |                           | 0.08 (0.02) | 0.01 (0.00) | 0.00 (0.00) |
| F/B ratio$^a$           |                           | 2.91 (0.34) | 23.33 (4.84) | 85.54 (26.61) |

*Expressed as % injected dose. Each value represents the mean (SD) for four animals.

Table 3. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_{14}$ in mice.

| Tissue                  | Time after administration | 10 min | 60 min | 180 min |
|-------------------------|---------------------------|--------|--------|---------|
| Blood                   |                           | 2.06 (0.18) | 0.14 (0.07) | 0.07 (0.01) |
| Liver                   |                           | 0.46 (0.06) | 0.10 (0.08) | 0.07 (0.01) |
| Kidney                  |                           | 9.88 (5.74) | 2.60 (2.40) | 1.20 (0.61) |
| Small-intestine         |                           | 0.49 (0.05) | 0.15 (0.10) | 0.09 (0.03) |
| Large-intestine         |                           | 0.39 (0.06) | 0.05 (0.01) | 0.17 (0.07) |
| Spleen                  |                           | 0.42 (0.09) | 0.11 (0.15) | 0.06 (0.01) |
| Pancreas                |                           | 0.56 (0.14) | 0.07 (0.04) | 0.05 (0.02) |
| Lung                    |                           | 1.59 (0.16) | 0.14 (0.05) | 0.07 (0.02) |
| Heart                   |                           | 1.09 (0.44) | 0.06 (0.02) | 0.04 (0.03) |
| Stomach                 |                           | 0.29 (0.16) | 0.05 (0.05) | 0.04 (0.03) |
| Bone (Femur)            |                           | 11.65 (0.49) | 12.56 (3.09) | 11.29 (0.62) |
| Muscle                  |                           | 0.87 (0.51) | 0.09 (0.06) | 0.09 (0.07) |
| Brain                   |                           | 0.10 (0.04) | 0.03 (0.02) | 0.02 (0.02) |
| F/B ratio$^a$           |                           | 5.69 (0.42) | 102.00 (41.75) | 171.85 (26.47) |

*Expressed as % injected dose. Each value represents the mean (SD) for five animals.

The biodistribution of $^{67}$Ga-DOTA-(Asp)$_{14}$ after pretreatment of normal mice with alendronate (20 mg/kg) is presented in Table 6. Table 7 and reference 29 show biodistribution of $^{67}$Ga-DOTA-Bn-SCN-HBP with or without pretreatment of alendronate (20 mg/kg). Although pretreatment with the same dose of alendronate significantly inhibited the accumulation of $^{67}$Ga-DOTA-Bn-SCN-HBP in bone (17.44%ID/g at 10 min, 22.28%ID/g at 60 min, 2.34%ID/g at 3 h), alendronate had comparatively little effect on the bone accumulation of $^{67}$Ga-DOTA-(Asp)$_{14}$.

Protein-binding Assay

Proportions of $^{67}$Ga-DOTA-(Asp)$_n$ (n = 2, 5, 8, 11, or 14) and $^{67}$Ga-DOTA-Bn-SCN-HBP bound to serum protein (Figure 5) shows that the binding of $^{67}$Ga-DOTA-(Asp)$_n$ compounds to serum proteins decreased with an increase in the length of the aspartic acid chain. This is a specific component of bone tissues, leading to targeting of bone tissues. In a previous study, it was reported that the in vitro binding profile of Fmoc-(Asp)$_n$ (n = 2, 4, 6, 8, or 10) to hydroxyapatite increased with the increase in the length of the peptide. Here a similar strategy was applied using aspartic acid peptides as the carrier to bone tissues instead of bisphosphonate. Indeed, we have demonstrated that the binding of $^{67}$Ga-DOTA-(Asp)$_n$ (n = 5, 8, 11, or 14) to hydroxyapatite increased with increased length of the aspartic acid peptide. This

Discussion

Previously, we introduced the concept of radiometal complex-conjugated bisphosphonate compounds for the development of bone-seeking radiopharmaceuticals [42,43]. Moreover, in recent years, superior activities of newly developed radiogallium complex-conjugated bisphosphonate compounds have been reported by us and other groups [30–34]. In these drug compounds, the bisphosphonate structure has high affinity for hydroxyapatite, which is a specific component of bone tissues, leading to targeting of bone tissues. In a previous study, it was reported that the in vitro binding profile of Fmoc-(Asp)$_n$ (n = 2, 4, 6, 8, or 10) to hydroxyapatite increased with the increase in the length of the
result is consistent with the previous study and was reflected by bone accumulation of $^{67}$Ga-DOTA-(Asp)$_{14}$ in biodistribution experiments. Moreover, these biodistribution experiments showed greater bone accumulation with increasing length of the peptide conjugates from $^{67}$Ga-DOTA-(Asp)$_2$ to $^{67}$Ga-DOTA-(Asp)$_{11}$. The longer compounds $^{67}$Ga-DOTA-(Asp)$_{11}$ and $^{67}$Ga-DOTA-(Asp)$_{14}$ accumulated equally in bone and showed superior biodistribution characteristics as that of bone imaging radiopharmaceuticals, with high accumulation in bone and rapid clearance from other tissues. Despite lower bone accumulation than the bisphosphonate $^{67}$Ga-DOTA-Bz-SCN-HBP, the bone/blood ratios of radioactivity after injection of $^{67}$Ga-DOTA-(Asp)$_{14}$ and $^{67}$Ga-DOTA-(Asp)$_{14}$, which are an index as bone imaging, were comparable or higher (Figure 6), presumably due to more rapid blood clearance than $^{67}$Ga-DOTA-Bz-SCN-HBP. This may reflect the lower serum protein binding ratios of $^{67}$Ga-DOTA-(Asp)$_{11}$ and $^{67}$Ga-DOTA-(Asp)$_{14}$ compared to that of $^{67}$Ga-DOTA-Bz-SCN-HBP (Figure 5).

We assumed that the high accumulation of radioactivity in the bone after injection of these compounds was due to hydroxyapatite binding of bisphosphonate or aspartic acid structures in bone tissues. To estimate the hydroxyapatite binding of these compounds, alendronate inhibition experiments were performed in vitro and in vivo. In these hydroxyapatite binding assays, $^{67}$Ga-DOTA-(Asp)$_{14}$ and $^{67}$Ga-DOTA-Bn-SCN-HBP binding was inhibited by alendronate, confirming that the mechanism by which $^{67}$Ga-DOTA-(Asp)$_{14}$ and $^{67}$Ga-DOTA-Bn-SCN-HBP accumulate in bone involves coordination of their functional groups to the Ca$^{2+}$ in hydroxyapatite crystals [45]. However, $^{67}$Ga-DOTA-Bn-SCN-HBP binding was inhibited by lower concentrations of alendronate compared with $^{67}$Ga-DOTA-(Asp)$_{14}$. Moreover, in biodistribution experiments, the inhibition of radioactive bone accumulation by alendronate was greater after injection of $^{67}$Ga-DOTA-Bn-SCN-HBP than that of $^{67}$Ga-DOTA-(Asp)$_{14}$. Although the precise mechanisms remain unclear, the binding patterns of these compounds to hydroxyapatite may differ. Wang et al. reported that alendronate and (D-Asp)$_{10}$, which were used as bone-targeting moieties on conjugated fluorescein isothiocyanate

### Table 4. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_{11}$ in mice.$^a$

| Tissue          | 10 min | 60 min | 180 min |
|-----------------|--------|--------|---------|
| Blood           | 1.51 (0.16) | 0.11 (0.02) | 0.03 (0.01) |
| Liver           | 0.44 (0.12) | 0.07 (0.01) | 0.05 (0.01) |
| Kidney          | 16.04 (7.49) | 1.76 (1.38) | 0.80 (0.21) |
| Small-intestine | 0.41 (0.04) | 0.27 (0.37) | 0.05 (0.02) |
| Large-intestine | 0.27 (0.02) | 0.06 (0.06) | 0.13 (0.05) |
| Spleen          | 0.31 (0.08) | 0.09 (0.06) | 0.04 (0.02) |
| Pancreas        | 0.62 (0.20) | 0.07 (0.06) | 0.05 (0.01) |
| Lung            | 1.11 (0.16) | 0.12 (0.09) | 0.04 (0.01) |
| Heart           | 0.55 (0.04) | 0.08 (0.05) | 0.02 (0.02) |
| Stomach$^b$     | 0.21 (0.02) | 0.18 (0.35) | 0.04 (0.01) |
| Bone (Femur)    | 13.09 (11.6) | 16.30 (3.58) | 13.91 (1.93) |
| Muscle          | 0.48 (0.06) | 0.13 (0.11) | 0.08 (0.05) |
| Brain           | 0.05 (0.02) | 0.02 (0.01) | 0.01 (0.01) |

F/B ratio$^c$ 8.71 (0.73) 156.07 (45.00) 501.32 (156.89)

$^a$Expressed as % injected dose. Each value represents the mean (SD) for five animals.

$^b$Expressed as % injected dose.

$^c$Femur/blood ratio.

### Table 5. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_{14}$ in mice.$^a$

| Tissue          | 10 min | 60 min | 180 min |
|-----------------|--------|--------|---------|
| Blood           | 1.61 (0.09) | 0.07 (0.01) | 0.03 (0.01) |
| Liver           | 0.39 (0.06) | 0.05 (0.01) | 0.05 (0.01) |
| Kidney          | 12.43 (5.81) | 0.99 (0.17) | 0.76 (0.10) |
| Small-intestine | 0.38 (0.06) | 0.08 (0.02) | 0.05 (0.02) |
| Large-intestine | 0.30 (0.04) | 0.04 (0.01) | 0.15 (0.08) |
| Spleen          | 0.42 (0.11) | 0.07 (0.02) | 0.03 (0.01) |
| Pancreas        | 0.50 (0.02) | 0.07 (0.02) | 0.03 (0.01) |
| Lung            | 1.19 (0.14) | 0.08 (0.01) | 0.03 (0.00) |
| Heart           | 0.62 (0.06) | 0.06 (0.00) | 0.03 (0.00) |
| Stomach$^b$     | 0.24 (0.06) | 0.10 (0.07) | 0.02 (0.01) |
| Bone (Femur)    | 10.08 (0.86) | 12.81 (1.67) | 13.27 (1.15) |
| Muscle          | 0.57 (0.19) | 0.08 (0.02) | 0.05 (0.03) |
| Brain           | 0.05 (0.01) | 0.01 (0.00) | 0.01 (0.00) |

F/B ratio$^c$ 6.27 (0.66) 185.54 (46.89) 591.08 (221.41)

$^a$Expressed as % injected dose. Each value represents the mean (SD) for five animals.

$^b$Expressed as % injected dose.

$^c$Femur/blood ratio.

### Table 6. Biodistribution of radioactivity after intravenous administration of $^{67}$Ga-DOTA-(Asp)$_{14}$ in mice with pretreatment of alendronate (20 mg/kg)$^a$.

| Tissue          | 10 min | 60 min | 180 min |
|-----------------|--------|--------|---------|
| Blood           | 1.94 (0.33) | 0.23 (0.05)** | 0.06 (0.02)** |
| Liver           | 2.20 (0.50)** | 1.39 (0.29)** | 1.27 (0.72)** |
| Kidney          | 16.66 (3.78) | 3.28 (0.82)** | 3.34 (0.92)** |
| Small-intestine | 0.53 (0.09)* | 0.22 (0.05)** | 0.29 (0.12)** |
| Large-intestine | 0.40 (0.08)* | 0.08 (0.01)** | 0.33 (0.07)** |
| Spleen          | 1.86 (0.98)** | 1.03 (0.35)** | 0.89 (0.59)** |
| Pancreas        | 0.72 (0.12)** | 0.15 (0.02)** | 0.12 (0.07)* |
| Lung            | 5.86 (3.64)* | 4.07 (2.99)* | 2.49 (1.78)* |
| Heart           | 0.88 (0.18)* | 0.24 (0.08)** | 0.15 (0.07)** |
| Stomach$^b$     | 0.36 (0.09)* | 0.15 (0.12) | 0.11 (0.04)** |
| Bone (Femur)    | 8.59 (0.55)** | 11.81 (1.95) | 12.88 (2.30) |
| Muscle          | 0.53 (0.11) | 0.11 (0.07) | 0.05 (0.02) |
| Brain           | 0.05 (0.01) | 0.02 (0.00) * | 0.01 (0.00) |

F/B ratio$^c$ 4.50 (0.63)** | 52.96 (17.20)** | 229.73 (67.08)**

$^a$Expressed as % injected dose. Each value represents the mean (SD) for five or six animals.

$^b$Expressed as % injected dose.

$^c$Femur/blood ratio.

$p<0.05$ vs. control (no pretreatment).

**$p<0.01$ vs. control (no pretreatment).
(FITC)-labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (P-ALN-FITC and P-D-Asp8-FITC). In the study, P-D-Asp8-FITC preferentially bound bone resorption surfaces, whereas P-ALN-FITC appeared to bind both formation and resorption surfaces in bone [46]. In hydroxyapatite binding experiments with different crystallinity, P-D-Asp8-FITC showed preferential binding to hydroxyapatite of higher crystallinity compared with P-ALN-FITC. These observations indicated that bisphosphonate and aspartic acid peptides have different modes of hydroxyapatite binding. Accordingly, 68Ga-DOTA-(Asp)14 PET imaging may give different information than that obtained by 99mTc-MDP bone scintigraphy methods. Since 99mTc-MDP mainly accumulates osteoblastic lesions in bone, it has been known that sensitivity 99mTc-MDP often shows false-negative in osteolytic bone metastases lesions, and consequently, its sensitivity is reduced [47]. On the contrary, 67Ga-DOTA-(Asp)n PET imaging may have a potential to improve its sensitivity. Meanwhile, in a previous 99mTc-MDP-bone scintigraphy study, treatments with bisphosphonate and alendronate may have caused false negative scintigraphy by producing competition between the drug and tracer, and blocking entrapment and accumulation of the tracer in bone [48]. In this study, pretreatment with alendronate inhibited bone accumulation of 67Ga-DOTA-Bn-SCN-HBP more effectively than that of 67Ga-DOTA-(Asp)14, suggesting that bisphosphonate-induced false negative scintigraphy is less likely to occur in 67Ga-DOTA-(Asp)14 PET.

Radiogallium complexes of 1,4,7-triazacyclononane-triacetic acid (NOTA) or triazacyclononane-phosphinate (TRAP) may produce radiocomplexes with a higher specific activity than DOTA, allowing the use of much lower concentrations of precursor for labeling [49]. Despite this, DOTA was used in this study because unlike receptor imaging, much higher specific activity is not necessary for hydroxyapatite-targeted bone imaging. Moreover, DOTA is more versatile and could be developed for both imaging and therapeutics. Since the DOTA ligand forms a stable complex with not only gallium (67/68Ga), but also lutetium (177Lu) and yttrium (90Y), which are beta particle emitters as radionuclides for therapy, furthermore, bismuth (213Bi) as an alpha emitter could be applicable, its application to therapy from diagnosis could be made available. That is, radiometal complexes of DOTA-(Asp)n for radionuclide therapy could be useful as agents for the palliation of metastatic bone pain.

### Table 7. Biodistribution of radioactivity after intravenous administration of 67Ga-DOTA-Bn-SCN-HBP in mice with pretreatment of alendronate (20 mg/kg).

| Tissue          | 10 min (Mean (% injected dose)) | 1 h (Mean (% injected dose)) | 3 h (Mean (% injected dose)) |
|-----------------|---------------------------------|-------------------------------|------------------------------|
| Blood           | 2.36 (0.20)**                   | 0.87 (0.10)**                 | 0.26 (0.05)**                |
| Liver           | 1.59 (0.28)**                   | 1.16 (0.21)**                 | 0.54 (0.19)**                |
| Kidney          | 13.84 (2.67)**                  | 8.13 (1.39)**                 | 6.42 (1.27)**                |
| Small-intestine | 0.61 (0.08)*                    | 0.55 (0.07)**                 | 0.38 (0.12)**                |
| Large-intestine | 0.37 (0.05)*                    | 0.18 (0.01)**                 | 0.38 (0.11)**                |
| Spleen          | 1.42 (0.19)**                   | 1.10 (0.25)**                 | 0.69 (0.36)**                |
| Pancreas        | 0.87 (0.15)**                   | 0.36 (0.09)**                 | 0.25 (0.06)**                |
| Lung            | 3.06 (0.78)**                   | 1.78 (0.18)**                 | 0.57 (0.22)**                |
| Heart           | 0.97 (0.22)*                    | 0.43 (0.05)**                 | 0.17 (0.05)*                 |
| Stomach         | 0.47 (0.06)**                   | 0.33 (0.05)**                 | 0.23 (0.10)**                |
| Bone (Femur)    | 8.59 (0.81)**                   | 13.47 (1.76)**                | 13.30 (2.10)**               |
| Muscle          | 0.57 (0.10)                     | 0.35 (0.14)                   | 0.19 (0.01)                  |
| Brain           | 0.06 (0.02)                     | 0.04 (0.01)                   | 0.02 (0.01)**                |
| F/B ratio       | 3.64 (0.20)**                   | 15.82 (3.48)**                | 51.38 (5.91)**               |

*Expressed as % injected dose. Each value represents the mean (SD) for five or six animals.

**Expressed as % injected dose.

*p < 0.05 vs. control (no pretreatment, Reference 29).

**p < 0.01 vs. control (no pretreatment, Reference 29).

doi:10.1371/journal.pone.0084335.t007

Figure 5. Serum protein binding. Serum protein binding ratios of 67Ga-DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) and 67Ga-DOTA-Bn-SCN-HBP. Data are expressed as the mean ± SD for four samples. doi:10.1371/journal.pone.0084335.g005

Figure 6. Bone/blood radio. Bone/blood ratio of radioactivity after injection of 67Ga-DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) and 67Ga-DOTA-Bn-SCN-HBP. Data are expressed as the mean ± SD. doi:10.1371/journal.pone.0084335.g006
In conclusion, the $^{68}$Ga-DOTA complex-conjugated aspartic acid peptides $^{68}$Ga-DOTA-(Asp)$^n$ showed ideal biodistribution characteristics as bone scintigraphy agents. Therefore, these agents may facilitate the drug design of PET tracers with $^{68}$Ga for the diagnosis of bone disorders, such as bone metastases. Further studies are required to determine whether $^{68}$Ga-DOTA-(Asp)$^n$ can provide additional information to that of bone scintigraphy, and to develop these compounds for radiolabel therapy.

Author Contributions

Conceived and designed the experiments: KO AO. Performed the experiments: KO AI KT. Analyzed the data: KO AI. Contributed reagents/materials/analysis tools: YK TK KS. Wrote the paper: KO.

References

1. Yoneeda T, Sasai A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32: 73–84.
2. Schultmann G, He, Geer F, Biér F, Kallflell FA, Thomas FD (1975) Technetium-99m-methylene diphosphonate: a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 16: 744–755.
3. Domestadt PA, Coupal JJ, Kim EE, Blake JS, DeLand FH (1989) $^{99m}$Tc-hydroxyethylene diphosphonate: a new bone imaging agent with a low tin content. Radiology 163: 209–211.
4. Love C, Din AS, Tomas MB, Kalaparambath TP, Palestor CJ (2003) Radiolabelled bone imaging: an illustrative review. Radiographics 23: 341–358.
5. Mari C, Cattafau A, Carrio I (1999) Bone scintigraphy and metabolic disorders. Q J Med 92: 259–267.
6. Lavender JP, Khan RA, Hughes SP (1979) Blood flow and tracer uptake in normal and abnormal canine bone: comparisons with Sr-85 microspheres, Kr-85 and $^{99m}$Tc-MDP. J Nucl Med 20: 413–418.
7. Budd RS, Hodgson GS, Hart WS (1989) The relation of radionuclide uptake by bone to the rate of calcium mineralization. I. Experimental studies using $^{99m}$Tc and $^{99m}$Tc-MDP. J Nucl Med 30: 314–317.
8. Budd RS, Hodgson GS, Hart WS (1989) The relation of radionuclide uptake by bone to the rate of calcium mineralization. II. Patient studies using $^{99m}$Tc-MDP. J Nucl Med 30: 318–320.
9. Galasko CS (1980) Mechanism of uptake of bone imaging isotopes by skeletal metastases. Cancer 46: 565–583.
10. Libson K, Deutsch E, Barnett BL (1980) Structural characterization of a technetium-99m-diphosphonate complex. Implications for the chemistry of technetium-99m skeletal imaging agents. J Am Chem Soc 102: 2476–2481.
11. Chao SL, Zodhiati A, Deutsch E, Heinegard D (1986) Effect of pH on the formation of $^{99m}$TcB$_2$H$_6$MDP radiopharmaceutical analogues. Int J Appl Radiat Isot 37: 1537–1548.
12. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H (2006) Development of a novel $^{99m}$Tc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 47: 2042–2047.
13. Verbeke K, Rousenki J, Clemens B, Vanhille H, de Groot T, et al. (2002) Development of a conjugate of $^{99m}$Tc-EC with aminomethylene diphosphonate in the search for a bone tracer with fast clearance from soft tissue. Bioconjug Chem 13: 667–679.
14. Palma E, Oliveira BI, Correia JD, Gano I, Maria L, et al. (2007) A new bisphosphonate-containing $^{99m}$Tc-tricarbonyl complex potentially useful as a bone-seeking agent: synthesis and biological evaluation. J Biol Inorg Chem 12: 659–679.
15. de Rosales RTM, Finucane C, Mather SJ, Blower PJ (2010) Bisphosphonates: Metal complexes for the diagnosis and therapy of bone metastases. Chem Commun: 4847–4849.
16. Ogawa K, Mukai T, Arano Y, Hanaoka H, Hashimoto K, et al. (2004) Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm 47: 753–761.
17. Ogawa K, Mukai T, Arano Y, Otsuka A, Ueda M, et al. (2006) Rhenium-186-monomannosamonomethylconjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33: 513–520.
18. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, et al. (2005) Development of a rhenium-186-labeled Mg3-labeled bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16: 751–757.
19. Ogawa K, Mukai T, Arano Y, Kawai H, Takamura N, et al. (2009) Rhenium-186-labeled bisphosphonate derivative. J Labelled Cmp Radiopharm 47: 753–761.
20. Ogawa K, Mukai T, Arano Y, Hanaoka H, Hashimoto K, et al. (2004) Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm 47: 753–761.
21. Ogawa K, Mukai T, Arano Y, Otsuka A, Ueda M, et al. (2006) Rhenium-186-monomannosamonomethylconjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33: 513–520.
22. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, et al. (2005) Development of a rhenium-186-labeled Mg3-labeled bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16: 751–757.
23. Ogawa K, Mukai T, Arano Y, Kawai H, Takamura N, et al. (2009) Rhenium-186-labeled bisphosphonate derivative. J Labelled Cmp Radiopharm 47: 753–761.
24. Ogawa K, Mukai T, Arano Y, Otsuka A, Ueda M, et al. (2006) Rhenium-186-monomannosamonomethylconjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33: 513–520.
25. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, et al. (2005) Development of a rhenium-186-labeled Mg3-labeled bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16: 751–757.
26. Ogawa K, Mukai T, Arano Y, Kawai H, Takamura N, et al. (2009) Rhenium-186-labeled bisphosphonate derivative. J Labelled Cmp Radiopharm 47: 753–761.
27. Ogawa K, Mukai T, Arano Y, Otsuka A, Ueda M, et al. (2006) Rhenium-186-monomannosamonomethylconjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33: 513–520.
28. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, et al. (2005) Development of a rhenium-186-labeled Mg3-labeled bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16: 751–757.
47. Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, et al. (2009) Detection of bone metastases in patients with lung cancer: $^{99m}$Tc-MDP planar bone scintigraphy, $^{18}$F-fluoride PET or $^{18}$F-FDG PET/CT. Eur J Nucl Med Mol Imaging 36: 1807–1812.

48. Demirkan B, Baskan Z, Alacacioglu A, Gorken IB, Bekis R, et al. (2005) False negative bone scintigraphy in a patient with primary breast cancer: a possible transient phenomenon of bisphosphonate (alendronate) treatment. Tumori 91: 77–80.

49. Notni J, Pohle K, Wester HJ (2012) Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res 2: 28.